Contact: +91-9711224068
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal
International Journal of Pharmaceutical and Clinical Research

Vol. 6, Issue 1, Part A (2024)

Nanovaccine approach to prevent binding of SARS-CoV-2 surface glycoprotein with ACE2 and TMPRSS2 receptor

Author(s):

Ashish Shivram Ramteke

Abstract:

The present worldwide health risk through the COVID-19 needs a quick arrangement of modern therapeutic strategies available. The role of nanomedicine is highly suitable against this “entity”. Nano interference is argued in terms of developing significant nanocarriers to counter the standard barriers of antiviral and biological therapeutics. This way promotes the safe and possible delivery of available therapeutic strategies by modified nanocarriers, inhibiting the primary interactions of spike glycoprotein to host cell surface receptors, and disturb vision formation. Controlling and terminating the spread and reappearance of this pandemic commands a safe and beneficial vaccine options. Nanocarriers have probable to outline risk-free and possible immunization ways for SARS-CoV-2 vaccine candidates like protein constructs and nucleic acids.

Pages: 41-52  |  96 Views  34 Downloads


International Journal of Pharmaceutical and Clinical Research
How to cite this article:
Ashish Shivram Ramteke. Nanovaccine approach to prevent binding of SARS-CoV-2 surface glycoprotein with ACE2 and TMPRSS2 receptor. Int. J. Pharm. Clin. Res. 2024;6(1):41-52. DOI: 10.33545/26647591.2024.v6.i1a.78
Call for book chapter